stoxline Quote Chart Rank Option Currency Glossary
  
Harmony Biosciences Holdings, Inc. (HRMY)
34.3299  0.32 (0.94%)    07-16 10:48
Open: 34.33
High: 34.6
Volume: 80,861
  
Pre. Close: 34.01
Low: 33.85
Market Cap: 1,950(M)
Technical analysis
2024-07-16 10:19:30 AM
Short term     
Mid term     
Targets 6-month :  40.92 1-year :  47.8
Resists First :  35.04 Second :  40.92
Pivot price 32.11
Supports First :  31.04 Second :  28.56
MAs MA(5) :  33.73 MA(20) :  31.44
MA(100) :  30.85 MA(250) :  31.1
MACD MACD :  1 Signal :  0.7
%K %D K(14,3) :  81.4 D(3) :  78.5
RSI RSI(14): 66.3
52-week High :  39.26 Low :  18.61
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ HRMY ] has closed below upper band by 19.4%. Bollinger Bands are 71.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 34.77 - 34.91 34.91 - 35.06
Low: 33.33 - 33.47 33.47 - 33.64
Close: 33.74 - 33.97 33.97 - 34.24
Company Description

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Headline News

Tue, 16 Jul 2024
Piper Sandler Stays Bullish on Harmony Biosciences stock post management meeting - Investing.com

Mon, 15 Jul 2024
Harmony Biosciences Holdings (NASDAQ:HRMY) Has A Rock Solid Balance Sheet - Simply Wall St

Sun, 14 Jul 2024
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Duality Advisers LP - Defense World

Sat, 13 Jul 2024
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Position Increased by LSV Asset Management - MarketBeat

Wed, 03 Jul 2024
Hennion & Walsh Asset Management Inc. Sells 2,458 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World

Fri, 07 Jun 2024
Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 57 (M)
Shares Float 35 (M)
Held by Insiders 19.7 (%)
Held by Institutions 91.5 (%)
Shares Short 8,130 (K)
Shares Short P.Month 7,090 (K)
Stock Financials
EPS 2.31
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.06
Profit Margin 22.2 %
Operating Margin 33.6 %
Return on Assets (ttm) 16.2 %
Return on Equity (ttm) 28.7 %
Qtrly Rev. Growth 29.7 %
Gross Profit (p.s.) 0
Sales Per Share 10.87
EBITDA (p.s.) 4.01
Qtrly Earnings Growth 39.5 %
Operating Cash Flow 208 (M)
Levered Free Cash Flow 202 (M)
Stock Valuations
PE Ratio 14.68
PEG Ratio 0.6
Price to Book value 3.75
Price to Sales 3.13
Price to Cash Flow 9.3
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android